explore -WSS

explore

author：entertainment 2025-09-29 16:35:37 - browse：71851

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Unmasking the 'centricity' illusion in clinical trials

knowledge

entertainment

explore

WSS

Clinicians often fail to acknowledge the pain caused by long Covid

Senators tussle over abortion against the backdrop of a presidential campaign

Finland to offer bird flu vaccine to select groups of people, a possible global first

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

STAT wants to know your pick for a great summer read or listen

Why we need mandatory labeling of GMO products

focus

explore

entertainment

Bright Health sells Medicare Advantage business to Molina

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Virginia high school admissions case could be legal follow

BD to buy Edwards patient monitoring unit for $4.2 billion

Wildfire smoke exposes gaps in outdoor worker protections

Some medical students still think black patients feel less pain

How to save PrEP access — and even expand it

FDA approves Moderna’s RSV vaccine, its second licensed product

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New research sheds light on how often breast cancer is overdiagnosed

hotspot

Louisiana bill approved classifying abortion pills as controlled substances

Congress: Prevent baby formula shortages by passing a new bill

Stopping antidepressants leads to symptoms for 1 in 6 patients

U.S. death rates show how politics are affecting public health

Medical students need to learn the potent medicine of empathy

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

knowledge

entertainment

explore

focus